The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 24, 2021

Filed:

Sep. 11, 2017
Applicant:

Janssen Biotech, Inc., Horsham, PA (US);

Inventors:

Chen Ni Chin, Devon, PA (US);

John Lee, North Wales, PA (US);

Timothy McCabe, Doylestown, PA (US);

Jill Mooney, San Diego, CA (US);

Michael Naso, Swarthmore, PA (US);

William Strohl, Bridgewater, NJ (US);

Assignee:

JANSSEN BIOTECH, INC., Horsham, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C07K 16/46 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); C12N 15/82 (2006.01); A61P 35/00 (2006.01); C07K 14/525 (2006.01); C07K 14/705 (2006.01); C07K 14/75 (2006.01); C07K 14/78 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 14/525 (2013.01); C07K 14/705 (2013.01); C07K 14/75 (2013.01); C07K 14/78 (2013.01); C07K 16/2878 (2013.01); C12N 15/8257 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/24 (2013.01); C07K 2317/50 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/033 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01);
Abstract

BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.


Find Patent Forward Citations

Loading…